<DOC>
	<DOC>NCT02486354</DOC>
	<brief_summary>This study was a single-arm, multi-center, prospective, phase 3 trial aimed to evaluate the efficacy and safety of icotinib in patients with locally advanced or metastatic NSCLC after failure of at least one platinum-based chemotherapy regimen.</brief_summary>
	<brief_title>Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically or cytologically confirmed locally advanced/metastatic (stage IIIB/stage IV, using the American Joint Committee on Cancer [AJCC] 6th edition of tumornodemetastasis [TNM] staging system) NSCLC patients Progressed after at least one platinumbased chemotherapy regimen at entry Eastern Cooperative Oncology Group (ECOG) performance status (PS) 02 At least one measurable lesion by Response Evaluation Criteria in Solid Tumors version 1.0 Adequate hematologic and biochemical values Patients with symptomatic brain metastases Malignant tumor within the previous five years Severe infection; congestive heart failure Previous treatment with drugs targeting EGFR History of interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>